A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222334

Enrollment

264

Registered

2013-12-19

Start date

2013-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Interventions

investigational material(s) Generic name etc : CIM331 INN of investigational material : nemolizumab Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Atopic dermatitis patients

Exclusion criteria

Exclusion criteria: - Serological evidence of hepatitis B virus or hepatitis C virus infection - Known human immunodeficiency virus infection - Evidence of tuberculosis (TB) infection

Design outcomes

Primary

Measure	Time frame
pruritis Visual Analogue Scale (VAS)	—

Secondary

Measure	Time frame
Dermatitis Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), static Investigator's Global Assessment (sIGA), Body Surface Area of Atopic Dermatitis involvement	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026